Individual Investors Are Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) Biggest Owners and Were Hit After Market Cap Dropped CN¥372m

Simply Wall StDec 19 18:12 ET

Zhejiang Shapuaisi Pharmaceutical Secures Clinical Trial Approval for Eye Drops

MT NewswiresDec 10 03:05 ET

Zhejiang Shapuaisi Pharmaceutical (603168.SH): The hydrochloride cetirizine eye drops have received a clinical trial approval notice.

Gelonghui on December 9th, zhejiang shapuaisi (603168.SH) announced that the company's levocetirizine hydrochloride eye drops obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (Notice No.: 2024LP02825), and the company plans to conduct clinical trials after the conditions are met. This product is used to treat eye itching associated with allergic conjunctivitis.

Gelonghui FinanceDec 9 03:16 ET

Shapuaisi Pharmaceutical Shareholders Plan to Reduce Stakes; Shares Down 10%

MT NewswiresNov 22 02:06 ET

November 22nd A-share investment lightning rod︱Changguang Huaxin: Shareholders Guotou Chuangye Ningbo Fund, Yili Suxin, and Nanjing Daofeng plan to collectively reduce their shareholding by no more than 2.01%.

*Shenzhen Coship Electronics: Termination of the application for reorganization and pre-reorganization to the court.

Gelonghui FinanceNov 21 09:15 ET

Zhejiang Shapuaisi Pharmaceutical (603168.SH): Chen Dekang and Shanghai Jingxing plan to collectively reduce their shareholding by no more than 5%.

According to Gelonghui on November 21, zhejiang shapuaisi pharmaceutical (603168.SH) announced that Mr. Chen Dekang plans to reduce his shareholding due to personal fund needs. Starting from the date of this announcement, within three months after 15 trading days, from December 13, 2024, to March 12, 2025, he will reduce no more than 3,791,616 shares through centralized bidding trading, which does not exceed 1.00% of the company's total share capital; within three months after the 15 trading days from the date of the announcement, no more than 3,791,616 shares will be reduced through block trading, which also does not exceed 1.00% of the company's total share capital.

Gelonghui FinanceNov 21 06:24 ET